NEA Management Company’s VistaGen Therapeutics VTGN Stock Holding History

NEA Management Company’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-543,420	Closed	-$14.3M	–	60
2022 Q2	$14.3M	Hold	543,420	–	–	0.74%	28
2022 Q1	$20.2M	Hold	543,420	–	–	0.58%	27
2021 Q4	$31.8M	Hold	543,420	–	–	0.64%	23
2021 Q3	$44.7M	Hold	543,420	–	–	0.53%	20
2021 Q2	$51.4M	Hold	543,420	–	–	0.67%	23
2021 Q1	$34.7M	Buy	543,420 +231,420	+74%	+$15.4M	0.78%	29
2020 Q4	$18.2M	Buy	+312,000	New	+$7.96M	0.48%	38

Other funds holding VTGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NEA Management Company's VTGN Position: Q3 2022 in Review

NEA Management Company sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 543,420 shares — an estimated $14.3M sold.

NEA Management Company first reported a position in VTGN in Q4 2020 and held it in 7 quarters. The position peaked at $51.4M in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

NEA Management Company reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
NEA Management Company sold 543,420 VistaGen Therapeutics shares in Q3 2022, an estimated $14.3M.
NEA Management Company first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 7 quarters.
NEA Management Company's VistaGen Therapeutics position peaked at $51.4M in Q2 2021.
92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on NEA Management Company's 13F filing for Q3 2022, filed 14 Nov 2022.